# An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects

> **NCT01666691** · PHASE2 · COMPLETED · sponsor: **Zafgen, Inc.** · enrollment: 160 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Beloranib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01666691
- **Lead sponsor:** Zafgen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2016-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01666691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01666691, "An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01666691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*